{
  "study_objective": "The primary objective of this clinical trial is to demonstrate the superior efficacy of bococizumab compared with placebo in reducing the risk of major CV events, a composite endpoint which includes adjudicated and confirmed CV death, non-fatal MI (myocardial infarction), non-fatal stroke, and hospitalization for unstable angina with urgent revascularization (as defined in Appendix 4), in subjects at high or very high risk of major CV events, who are on background lipid lowering treatment, and have an LDL-C \u2a7e70 mg/dL (1.81 mmol/L) or non-HDL-C \u2a7e100 mg/dL (2.59 mmol/L).",
  "inclusion_criteria": [
    "Informed Consent",
    "Compliance",
    "Age (\u2a7elegal age of majority for those with prior CVD event; other age criteria apply)",
    "Acceptance of administration of investigational product",        
    "Requirements for background lipid lowering treatment (with exceptions noted)",
    "Qualifying cardiovascular disease risk (criteria listed)",       
    "Qualifying lipid levels (LDL-C or non-HDL-C)",
    "Contraception requirements"
  ],
  "exclusion_criteria": [
    "Personnel involved in the conduct of the study",
    "Exclusionary prior CV events or planned revascularization procedures",
    "Participation in prior clinical research studies",
    "Other exclusionary conditions",
    "Childbearing potential and/or breastfeeding",
    "Latex sensitivity",
    "Apheresis",
    "Severe congestive heart failure",
    "Dialysis",
    "Chronic renal insufficiency",
    "Hypertension (poorly controlled)",
    "Cerebral hemorrhage risk",
    "Tissue donation",
    "Substance abuse",
    "Human immunodeficiency virus",
    "Prior or anticipated exposure to a PCSK9 inhibitor",
    "Depression (PHQ-9 score \u2a7e15 or positive score in question 9)",
    "Hypersensitivity to monoclonal antibodies",
    "Hepatitis (criteria listed)",
    "Creatine kinase elevations",
    "Amino transferase elevation",
    "Bilirubin elevation",
    "Malignancy",
    "Gastric bypass surgery",
    "Subjects not taking a statin"
  ],
  "primary_endpoints": [
    "Time from randomization to the first adjudicated and confirmed occurrence of a major CV event (composite endpoint: CV death, non-fatal MI, non-fatal stroke, and hospitalization for unstable angina needing urgent revascularization)"
  ],
  "secondary_endpoints": [
    "Time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of CV death, non-fatal MI, and non-fatal stroke",
    "Time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of all-cause death, non-fatal MI, non-fatal stroke, and hospitalization for unstable angina needing urgent revascularization",
    "Time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of all-cause death, non-fatal MI and non-fatal stroke",
    "Time from randomization to the first adjudicated and confirmed occurrence of hospitalization for unstable angina needing urgent revascularization",
    "Time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of CV death, non-fatal MI, non-fatal stroke, and hospitalization for unstable angina",
    "Time from randomization to the first adjudicated and confirmed occurrence of CV death",
    "Time from randomization to the first adjudicated and confirmed occurrence of any MI (fatal and non-fatal)",
    "Time from randomization to the first adjudicated and confirmed occurrence of fatal MI",
    "Time from randomization to the first adjudicated and confirmed occurrence of non-fatal MI",
    "Time from randomization to the first adjudicated and confirmed occurrence of any stroke (fatal and non-fatal)",
    "Time from randomization to the first adjudicated and confirmed occurrence of any stroke (fatal and non-fatal), of any etiology",       
    "Time from randomization to the first adjudicated and confirmed occurrence of fatal stroke",
    "Time from randomization to the first adjudicated and confirmed occurrence of non-fatal stroke",
    "Time from randomization to the first adjudicated and confirmed occurrence of hospitalization for unstable angina",
    "Time from randomization to the first adjudicated and confirmed occurrence of hospitalization for congestive heart failure (CHF)",      
    "Time from randomization to the first adjudicated and confirmed occurrence of any coronary revascularization procedure",
    "Time from randomization to the first adjudicated and confirmed occurrence of Coronary artery bypass graft surgery (CABG)",
    "Time from randomization to the first adjudicated and confirmed occurrence of Percutaneous coronary intervention (PCI)",
    "Time from randomization to the first adjudicated and confirmed occurrence of any arterial revascularizations",
    "Time from randomization to the first adjudicated and confirmed occurrence of all-cause death",
    "Percent change and nominal change from baseline at Week 14 and percent change from baseline to the last available post-randomization value in LDL-C (direct measure)",
    "Percent change from baseline at Week 14 in Non-HDL-C, Total cholesterol, VLDL-C, RLP-C, Apolipoprotein B (apo B), Lipoprotein(a) (Lp(a)), Triglycerides, HDL-C, Apolipoprotein A-I (apo A-I)",
    "Percent change from baseline at Week 14 in high sensitivity C-reactive protein (hs-CRP)",
    "Incidence, primary and secondary discharge diagnoses, overall length of stay, duration of stay in different medical care units, and discharge disposition for all-cause hospitalizations",
    "Incidence, primary and secondary discharge diagnoses, overall length of stay, duration of stay in different medical care units, and discharge disposition for CV hospitalizations",
    "Incidence of emergency room visits",
    "Incidence of physician office visits",
    "Incidence of outpatient rehabilitation visits",
    "Incidence of all-cause hospitalizations within 30 days of a previous hospitalization, primary and secondary discharge diagnoses, length of stay, and discharge disposition",
    "Incidence of CV hospitalizations within 30 days of a previous hospitalization, primary and secondary discharge diagnoses, length of stay, and discharge disposition",
    "Investigator reported adverse events (including Type 1 and 3 hypersensitivity reactions and injection site reactions), serious adverse events, vital signs, examination observations (physical and neurological examinations and cognitive testing), 12-lead ECG recordings, and safety laboratory tests (hematology, blood chemistry studies including liver function tests and creatine kinase tests, urinalysis studies, and ADA assessments)"
  ]
}